secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-06-11T20:30:16+00:00
Accession:  0001193125-26-267659
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum approves retention bonuses for CEO, CLO, CFO; accounting officer departs after restructuring
--------------------------------------------------------------------------------

- CEO Alex Sapir receives $370,040 retention bonus; CLO Curtis Oltmans $195,480; CFO Alan Musso $195,200.
- Bonuses payable on change in control or termination without cause after fulfilling transitional duties.
- VP+ level employees added to change-in-control severance if terminated within 6 months before a CIC.
- VP Finance & principal accounting officer Greg Tourangeau departs mutually; no disagreement on financial matters.
- Restructuring follows discontinuation of pociredir for sickle cell disease, previously disclosed May 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/0001193125-26-267659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526267659/fulc-20260605.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-267659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer